Page last updated: 2024-08-17

lysine and yttrium radioisotopes

lysine has been researched along with yttrium radioisotopes in 4 studies

Research

Studies (4)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (25.00)	18.2507
2000's	3 (75.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bakker, WH; Bernard, BF; Breeman, WA; de Jong, M; Krenning, EP; Mäcke, H; Rolleman, EJ; Visser, TJ	1
Barone, R; Bouterfa, H; Carlier, P; Chen, T; de Camps, J; Jamar, F; Krenning, EP; Kvols, LK; Labar, D; Mathieu, I; Pauwels, S; Schran, H; Smith, MC; Valkema, R; Walrand, S	1
Bouterfa, H; Bushnell, D; Carlisle, T; Connolly, M; Kahn, D; Karwal, M; Madsen, M; Menda, Y; Miller, S; O'Dorisio, S; O'Dorisio, T; Ponto, J; Squires, S; Walkner, W	1
Baidoo, K; Boswell, CA; Brechbiel, MW; Choyke, PL; Gunn, AJ; Milenic, DE; Xu, H	1

Trials

2 trial(s) available for lysine and yttrium radioisotopes

Article	Year
86Y-DOTA0)-D-Phe1-Tyr3-octreotide (SMT487)--a phase 1 clinical study: pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion. European journal of nuclear medicine and molecular imaging, 2003, Volume: 30, Issue:4 Topics: Adult; Aged; Amino Acids; Arginine; Cohort Studies; Cross-Over Studies; Dizziness; Drug Combinations; Female; Humans; Infusions, Intravenous; Kidney; Lysine; Male; Metabolic Clearance Rate; Middle Aged; Neuroendocrine Tumors; Octreotide; Organ Specificity; Radiation Dosage; Radiation Injuries; Radiation-Protective Agents; Radiometry; Radiopharmaceuticals; Tissue Distribution; Tomography, Emission-Computed; Vomiting; Yttrium Radioisotopes	2003
Effects of intravenous amino acid administration with Y-90 DOTA-Phe1-Tyr3-Octreotide (SMT487[OctreoTher) treatment. Cancer biotherapy & radiopharmaceuticals, 2004, Volume: 19, Issue:1 Topics: Adult; Aged; Amino Acids; Arginine; Carcinoid Tumor; Female; Humans; Infusions, Intravenous; Kidney; Lung Neoplasms; Lysine; Male; Meningioma; Middle Aged; Octreotide; Pancreatic Neoplasms; Radiopharmaceuticals; Yttrium Radioisotopes	2004

Article

Year

86Y-DOTA0)-D-Phe1-Tyr3-octreotide (SMT487)--a phase 1 clinical study: pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion.

European journal of nuclear medicine and molecular imaging, 2003, Volume: 30, Issue:4

Topics: Adult; Aged; Amino Acids; Arginine; Cohort Studies; Cross-Over Studies; Dizziness; Drug Combinations; Female; Humans; Infusions, Intravenous; Kidney; Lysine; Male; Metabolic Clearance Rate; Middle Aged; Neuroendocrine Tumors; Octreotide; Organ Specificity; Radiation Dosage; Radiation Injuries; Radiation-Protective Agents; Radiometry; Radiopharmaceuticals; Tissue Distribution; Tomography, Emission-Computed; Vomiting; Yttrium Radioisotopes

2003

Effects of intravenous amino acid administration with Y-90 DOTA-Phe1-Tyr3-Octreotide (SMT487[OctreoTher) treatment.

Cancer biotherapy & radiopharmaceuticals, 2004, Volume: 19, Issue:1

Topics: Adult; Aged; Amino Acids; Arginine; Carcinoid Tumor; Female; Humans; Infusions, Intravenous; Kidney; Lung Neoplasms; Lysine; Male; Meningioma; Middle Aged; Octreotide; Pancreatic Neoplasms; Radiopharmaceuticals; Yttrium Radioisotopes

2004

Other Studies

2 other study(ies) available for lysine and yttrium radioisotopes

Article	Year
D-lysine reduction of indium-111 octreotide and yttrium-90 octreotide renal uptake. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 1997, Volume: 38, Issue:12 Topics: Animals; Indium Radioisotopes; Kidney; Lysine; Male; Octreotide; Pentetic Acid; Radionuclide Imaging; Radiopharmaceuticals; Rats; Rats, Wistar; Tissue Distribution; Yttrium Radioisotopes	1997
Design, synthesis, and characterization of a dual modality positron emission tomography and fluorescence imaging agent for monoclonal antibody tumor-targeted imaging. Journal of medicinal chemistry, 2007, Sep-20, Volume: 50, Issue:19 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Binding, Competitive; Carbocyanines; Cell Line, Tumor; Chelating Agents; Drug Design; Flow Cytometry; Fluorescent Dyes; Humans; Immunoconjugates; Indium Radioisotopes; Isothiocyanates; Lysine; Pentetic Acid; Positron-Emission Tomography; Radioimmunoassay; Radiopharmaceuticals; Trastuzumab; Yttrium Radioisotopes	2007

Article

Year

D-lysine reduction of indium-111 octreotide and yttrium-90 octreotide renal uptake.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 1997, Volume: 38, Issue:12

Topics: Animals; Indium Radioisotopes; Kidney; Lysine; Male; Octreotide; Pentetic Acid; Radionuclide Imaging; Radiopharmaceuticals; Rats; Rats, Wistar; Tissue Distribution; Yttrium Radioisotopes

1997

Design, synthesis, and characterization of a dual modality positron emission tomography and fluorescence imaging agent for monoclonal antibody tumor-targeted imaging.

Journal of medicinal chemistry, 2007, Sep-20, Volume: 50, Issue:19

Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Binding, Competitive; Carbocyanines; Cell Line, Tumor; Chelating Agents; Drug Design; Flow Cytometry; Fluorescent Dyes; Humans; Immunoconjugates; Indium Radioisotopes; Isothiocyanates; Lysine; Pentetic Acid; Positron-Emission Tomography; Radioimmunoassay; Radiopharmaceuticals; Trastuzumab; Yttrium Radioisotopes

2007